难治性脑膜瘤患者肽受体放射性核素治疗的长期疗效、生存与毒性
研究纳入18例难治性脑膜瘤患者,于2004年1月至2019年12月接受177Lu或90Y标记生长抑素类似物PRRT。14例完成2周期评估者中12例(85.7%)达疾病控制,中位无进展生存期32.3个月,中位随访67.1个月时中位总生存期尚未达到,未观察到严重急性不良反应或2-4级血液学毒性。
要点
- 14例完成2周期PRRT评估的患者中12例(85.7%)达到疾病控制。
- 中位无进展生存期32.3个月,中位随访67.1个月时中位总生存期尚未达到。
- 未观察到严重急性不良反应、2-4级贫血/白细胞减少/血小板减少毒性及肾毒性、肝毒性或晚期放射不良反应。
核心结论
- PRRT在难治性脑膜瘤患者中显示出有前景的结局,疾病控制率高,无进展生存期和总生存期令人鼓舞,因此似乎是一种有利的治疗选择。
- 长期随访显示PRRT安全性良好,在该脑膜瘤患者队列中副作用很少。
研究设计与样本
- 研究纳入18例难治性脑膜瘤患者,表现为尽管接受手术或放疗仍进展或复发,或肿瘤无法手术且缺乏其他治疗选择。
- 患者于2004年1月至2019年12月接受177Lu标记或90Y标记的生长抑素类似物(DOTATATE、DOTATOC或HA-DOTATATE)PRRT。
- 疗效依据神经肿瘤疗效评估标准、实体瘤疗效评价标准和分子影像标准进行评估。
主要发现
- 大多数患者接受2周期PRRT,最多应用4周期。
- 平均总给药活度为12.7 GBq(范围:8.5-28.5 GBq)。
- 14例完成2周期PRRT后监测的患者中,12例(85.7%)达到疾病控制。
- 中位无进展生存期为32.3个月,中位随访67.1个月时中位总生存期尚未达到。
- 所有患者均耐受治疗,未出现任何严重急性不良反应;PRRT期间或之后未观察到常见不良事件评价标准2-4级贫血、白细胞减少或血小板减少毒性;长期随访期间未报告肾毒性、肝毒性或晚期放射不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Peptide receptor radionuclide therapy (PRRT) offers a promising treatment option by targeting the high density of somatostatin receptors overexpressed in meningiomas. The objective of this study aimed to evaluate the long-term outcome of PRRT in patients with refractory meningioma. PATIENTS AND METHODS: Eighteen patients with refractory meningioma, presenting with progression or recurrence despite surgery or radiotherapy or having inoperable tumors and lack of other therapeutic options, received PRRT with 177Lu-labeled or 90Y-labeled somatostatin analogs (DOTATATE, DOTATOC, or HA-DOTATATE) between January 2004 and December 2019. Treatment response was evaluated according to the Response Assessment in Neuro-Oncology, Response Evaluation Criteria in Solid Tumors, and molecular imaging criteria. RESULTS: Most patients received 2 cycles of PRRT, and up to 4 cycles were applied. The mean total administered activity was 12.7 GBq (range: 8.5-28.5 GBq). Of 14 patients monitored after 2 cycles of PRRT, disease control was reached in 12 (85.7%) patients. The median progression-free survival was 32.3 months, and the median OS has yet to be reached with a median follow-up of 67.1 months. All patients tolerated the therapy without any serious acute adverse effects. No Common Terminology Criteria for Adverse Event grades 2-4 anemia, leukopenia, or thrombocytopenia toxicities were observed during or after PRRT. No renal toxicity, hepatotoxicity, or late radiation adverse effects were reported during long-term follow-up. CONCLUSIONS: PRRT showed promising outcomes in patients with refractory meningiomas, with high disease control and encouraging progression-free survival and OS, and therefore appears to be a favorable therapeutic option. With long-term follow-up, PRRT demonstrated a favorable safety profile, resulting in very few side effects in this cohort of patients with meningioma.
引用
- Zhang J, Li D, Shi M, et al. Long-term Efficacy, Survival, and Toxicity of Peptide Receptor Radionuclide Therapy in Patients With Refractory Meningioma. Clin Nucl Med. 2025. PMID: 40320628. doi:10.1097/RLU.0000000000005845
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。